Therapeutic Targeting of Tumor Growth and Angiogenesis with a Novel Anti-S100A4 Monoclonal Antibody

Researchers from BIOMED Division at LEITAT Technological Center, in collaboration with the University of Barcelona, demonstrated the efficacy of a new approach for the treatment of human cancer in preclinical trials. The new strategy is based on the action of a monoclonal anti-body against S100A4, which is a key factor for tumoural growth. The blockage of S100A4 disrupts the communication of malignant cells.

Check the full publication here:

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0072480